JP2017528431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528431A5 JP2017528431A5 JP2017502821A JP2017502821A JP2017528431A5 JP 2017528431 A5 JP2017528431 A5 JP 2017528431A5 JP 2017502821 A JP2017502821 A JP 2017502821A JP 2017502821 A JP2017502821 A JP 2017502821A JP 2017528431 A5 JP2017528431 A5 JP 2017528431A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- inhibitor
- composition
- active
- metformin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025714P | 2014-07-17 | 2014-07-17 | |
| US62/025,714 | 2014-07-17 | ||
| PCT/US2015/040879 WO2016011335A1 (en) | 2014-07-17 | 2015-07-17 | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017528431A JP2017528431A (ja) | 2017-09-28 |
| JP2017528431A5 true JP2017528431A5 (enExample) | 2018-08-16 |
Family
ID=55079079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502821A Pending JP2017528431A (ja) | 2014-07-17 | 2015-07-17 | 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170173060A1 (enExample) |
| EP (1) | EP3169331A4 (enExample) |
| JP (1) | JP2017528431A (enExample) |
| KR (1) | KR20170026635A (enExample) |
| CN (1) | CN106687119A (enExample) |
| AU (1) | AU2015289511A1 (enExample) |
| CA (1) | CA2955425A1 (enExample) |
| IL (1) | IL250170A0 (enExample) |
| WO (1) | WO2016011335A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8999721B2 (en) | 2009-10-23 | 2015-04-07 | Therabrake, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| US20180099001A1 (en) | 2011-04-29 | 2018-04-12 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
| WO2016183535A1 (en) | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
| EP3393496B1 (en) | 2015-12-23 | 2023-10-11 | The Johns Hopkins University | Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions |
| US11564667B2 (en) | 2015-12-28 | 2023-01-31 | New York University | Device and method of restoring microbiota of newborns |
| US10398389B1 (en) | 2016-04-11 | 2019-09-03 | Pricewaterhousecoopers Llp | System and method for physiological health simulation |
| WO2017203367A2 (en) * | 2016-05-22 | 2017-11-30 | Volant Holdings Gmbh | Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof |
| AU2018219367A1 (en) * | 2017-02-10 | 2019-09-19 | Innovate Biopharmaceuticals, Inc. | Compositions and methods for treating disease associated with permeability of intestinal epithelium |
| WO2018204918A1 (en) * | 2017-05-05 | 2018-11-08 | Ardelyx, Inc. | Treatment of hepatic disorders |
| US20200199645A1 (en) * | 2017-09-08 | 2020-06-25 | Control Of Innate Immunity Technology Research Association | Device and method for diagnosis of alzheimer's symptoms |
| CN111587110A (zh) * | 2018-01-12 | 2020-08-25 | 麦提麦迪制药有限公司 | 治疗慢性炎症性疾病的方法 |
| KR102282490B1 (ko) | 2018-01-12 | 2021-07-28 | 주식회사 엠디헬스케어 | 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도 |
| AU2019228119A1 (en) * | 2018-03-02 | 2020-09-10 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| AU2019232145B2 (en) * | 2018-03-07 | 2024-08-08 | Teagasc - The Agriculture And Food Development Authority | A composition for type II diabetics and for use in providing sustained energy release over time |
| WO2020081369A1 (en) * | 2018-10-15 | 2020-04-23 | James Glenn Norman | Applied artificial intelligence technology for hormone therapy treatment |
| US10803981B2 (en) | 2018-10-15 | 2020-10-13 | James Glenn Norman | Applied artificial intelligence technology for hormone therapy treatment |
| KR102104507B1 (ko) * | 2019-08-23 | 2020-04-24 | 브릿지바이오테라퓨틱스(주) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 |
| WO2021069504A1 (en) * | 2019-10-11 | 2021-04-15 | F. Hoffmann-La Roche Ag | Drug dosage determination devices and methods |
| US20230241064A1 (en) * | 2020-01-08 | 2023-08-03 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor |
| CN117056370A (zh) * | 2020-03-19 | 2023-11-14 | 上海太美星云数字科技有限公司 | 医学数据处理方法、装置、设备和存储介质 |
| WO2022243459A1 (en) * | 2021-05-19 | 2022-11-24 | Charité - Universitätsmedizin Berlin | Computer assisted method for the evaluation of cardiac metabolism |
| CN113362925B (zh) * | 2021-06-29 | 2022-04-08 | 山东第一医科大学附属省立医院(山东省立医院) | 一种自动良肢位控制方法及设备 |
| CN114705871A (zh) * | 2022-04-12 | 2022-07-05 | 复旦大学附属中山医院 | 8异前列腺素F2α在重度哮喘诊断中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| KR20060076319A (ko) * | 2003-09-24 | 2006-07-04 | 콤비네이토릭스, 인코포레이티드 | 약물 조합들을 투여하는 치료 요법 |
| EP1919285A2 (en) * | 2005-07-28 | 2008-05-14 | Reliant Pharmaceuticals, Inc. | Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof |
| MX2009002166A (es) * | 2006-08-31 | 2009-03-12 | Eurand Inc | Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos. |
| US8999721B2 (en) * | 2009-10-23 | 2015-04-07 | Therabrake, Inc. | Method and system to provide personalized pharmaceutical compositions and dosages |
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| US9370528B2 (en) * | 2011-03-02 | 2016-06-21 | Volant Holdings Gmbh | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection |
| AU2014205553A1 (en) * | 2013-01-08 | 2015-07-09 | Volant Holdings Gmbh | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
-
2015
- 2015-07-17 WO PCT/US2015/040879 patent/WO2016011335A1/en not_active Ceased
- 2015-07-17 JP JP2017502821A patent/JP2017528431A/ja active Pending
- 2015-07-17 KR KR1020177004581A patent/KR20170026635A/ko not_active Withdrawn
- 2015-07-17 EP EP15822742.1A patent/EP3169331A4/en not_active Withdrawn
- 2015-07-17 AU AU2015289511A patent/AU2015289511A1/en not_active Abandoned
- 2015-07-17 CN CN201580050102.7A patent/CN106687119A/zh active Pending
- 2015-07-17 CA CA2955425A patent/CA2955425A1/en not_active Abandoned
-
2017
- 2017-01-17 US US15/407,394 patent/US20170173060A1/en not_active Abandoned
- 2017-01-17 IL IL250170A patent/IL250170A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102103426B1 (ko) | 당뇨병 신규 발병 저감용 조성물 | |
| JP2015503593A5 (enExample) | ||
| AU2011261117B2 (en) | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation | |
| JP5204846B2 (ja) | エタノールの影響に対して耐性を有する非オピオイド薬のｐＨ依存性制御放出医薬組成物 | |
| JP5619130B2 (ja) | 中性ビニルポリマーおよび賦形剤を含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物 | |
| HRP20210686T1 (hr) | Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom | |
| JP2015522029A5 (enExample) | ||
| JP2019048843A5 (enExample) | ||
| JP2017528516A5 (enExample) | ||
| JP2015503590A5 (enExample) | ||
| US20110311631A1 (en) | Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients | |
| RU2018120726A (ru) | Комбинации с гемкабеном для лечения заболеваний сердечно-сосудистой системы | |
| ES2525648T3 (es) | Formulaciones galénicas que comprenden Aliskiren | |
| JP2018065840A (ja) | 肝臓脂肪症単独又はｃ型肝炎ウイルス感染を伴った肝臓脂肪症の治療のための組成物、治療法及び診断法 | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| ES2623176T3 (es) | Composición farmacéutica de memantina | |
| Bader et al. | Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro | |
| KR20090114325A (ko) | 약제학적 제제 | |
| RU2014127884A (ru) | Способы лечения сердечно-сосудистого нарушения | |
| RU2016125229A (ru) | Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина | |
| JP2005538121A5 (ja) | 多重遅延放出抗ウイルス物質産物、その使用法と製剤 | |
| ES2299072T3 (es) | Procedimiento para la preparacion de formas medicamentosas con perfil de liberacion de principio activo estable. | |
| Kim et al. | Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial | |
| MXPA04006780A (es) | Formulaciones farmaceuticas de pravastatina y metodos para usarlas. | |
| WO2009048289A2 (en) | Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid |